cigna glp-1 program is ending employee coverage for weight-loss drugs like Wegovy and Zepbound starting July 1. The decision highlights growing debates around cost, access, and the future of obesity treatment. #Cigna #GLP1 # Glp-1 Obesity Drugs: Cigna drops

Tsuchihashi-Makaya M, Serizawa M, Yanai K, Katsuya T, Takeuchi F, Fujioka A, Yamori Y, Ogihara T, Kato N

Carnitine and pregnancy-related parameters Fakhrildin and Flayyih reported an improvement in weight of the reproductive organs (ovaries, uterine horns, vagina) and endometrial thickness, litter sizes as well as serum LH, FSH and E2 levels in pregnant mice (Swiss albino strain females aged between 12 to 14 weeks) given 0.5 and 1.0 mg/kg LC compared to the control group

These alternate metabolic routes lead to accumulation of toxic intermediates and advanced glycation end products, promoting inflammation, cellular dysfunction, apoptosis, and fibrosis within kidney tissues [24,25]

Patients with obesity who are at risk for low muscle mass, affecting both physical and metabolic function, may benefit from treatments that maximize fat mass reduction while preserving skeletal muscle, said Heymsfield, who is an LSU Boyd Professor and director of the Metabolism and Body Composition Laboratory